Product Overview
British Dragon Tesamorelin 5mg is one 5 mg vial of lyophilised tesamorelin, a GHRH analogue engineered to resist breakdown long enough to raise growth hormone in a predictable way. The molecule has an unusual status among the peptides on this site: a stabilised injectable version reached the market as Egrifta and later as Egrifta SV and WR, licensed for excess visceral fat in patients with lipodystrophy. That history gives the peptide something most of its neighbours lack, a documented dose and an adverse event table, though both belong to the licensed product rather than to the powder in this vial.
How it works is a two-step sequence. The peptide binds the GHRH receptor on the pituitary, which releases growth hormone, and the resulting growth hormone then drives IGF-1 production in the liver and in tissue. Both rises are transient, arriving within hours of an injection, and the meaningful clinical endpoint in the trials was a change in deep abdominal fat measured over months. Reported clearance figures differ by formulation: the label for the SV version describes an average of about eight minutes after a 1.4 mg subcutaneous injection, the WR version about eleven minutes, and the older general data give a 26-38 minute band.
Healthy users borrow the compound for a narrow purpose: stripping visceral fat and tightening a recomp phase, usually alongside a low daily amount of Somatrobol HGH if a direct growth hormone supply is wanted instead, or beside a mild oral such as Oxanabol to hold muscle in a deficit. The transfer from patients with lipodystrophy to healthy athletes has never been tested, and that gap is stated plainly rather than glossed over. WADA class S2 lists tesamorelin by name as permanently prohibited.
Research Dosing and Reconstitution
The only doses with any authority behind them belong to the licensed presentations: 2 mg daily for Egrifta and 1.4 mg daily for Egrifta SV, both subcutaneous. They are quoted as a reference frame for how the peptide behaves, not as a plan for the research vial, and no vendor cycle protocol for a lyophilised format was found.
| Beginner | Well below the licensed amounts, on a daily schedule, with the arithmetic of the vial worked out first |
| Intermediate | Approaching the licensed daily figure, injected at a consistent time each day |
| Advanced | At or near the licensed amount; nothing above it has a published basis of any kind |
| Female | No female-specific schedule appears in the sources; the licensed dose is not stratified by sex |
| Administration | Subcutaneous, daily, rotating sites; a 5 mg vial taken up in 1 mL of solvent reaches 5 mg/mL, where 1 mg is 20 units and 2 mg is 40 units on a U-100 syringe |
The coverage problem is worth spelling out, since it decides how anyone buys this product. At the licensed daily figure a 5 mg vial lasts a handful of days at most, so a real course means a stock of vials, and someone planning a fortnight around one vial is working with a dose far below the licensed range.
Visceral Fat and Line Context
Tesamorelin is not a stacking agent in the way an oral is. The clinical trials ran it as a single daily drug, and the additions below belong to the surrounding diet and training strategy rather than to the peptide. None of them has been evaluated with tesamorelin.
What to Expect
- Growth hormone and IGF-1. Both move within hours of an injection, which is the measurable part and not the part anyone notices.
- Deep abdominal fat. Reductions were recorded in long daily clinical use; the timescale is measured in months of consistent injections.
- Waist over scale. Visceral fat changes show up at the tape measure before they show on a bodyweight chart, which is why the tape is the better record.
- Daily commitment. An action lasting minutes means one injection per day, and a missed week is a week of lost exposure rather than a small delay.
- Limitation. The licensed population was adults with lipodystrophy; healthy trained users are extrapolation, and no trial supports that use.
- Limitation. A 5 mg vial is a few days of material at licensed amounts, so cost per day is far higher than the sticker price suggests.
- Limitation. Growth hormone signalling can push fasting glucose up, blood sugar has to be watched, and the peptide is banned in sport at all times.
Side Effects and Management
Most of this profile comes from the licensed product, which is one advantage this peptide has over its neighbours. The complaints are local first and metabolic second.
Vial Maths and Long-Term Monitoring
Two practical notes close this page. The mixed solution is the perishable part of the kit, and the markers worth tracking are metabolic rather than cosmetic, because that is where this peptide can actually cause harm.
